Provenge Tide Lifts All Immunotherapies; Price Cheers Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts scramble to revise revenue forecasts upward after Dendreon releases high-end price and plans to go it alone in Europe